Below is a representative AICC consultation report for a urinary tract infection PCR panel. Every patient detail is fictional, but the structure, depth, and clinical reasoning are exactly how a real consultation arrives.
For illustration only. Patient details are fictional.
| Medication | Dose | Duration | Renal Adjustment | Considerations |
|---|---|---|---|---|
| Nitrofurantoin monohydrate/macrocrystals | 100 mg PO twice daily | 5 days (uncomplicated cystitis) | Contraindicated if CrCl <30 mL/min; avoid if CrCl 30-60 mL/min due to reduced efficacy | Active against E. coli; achieves therapeutic urinary concentrations; not for pyelonephritis (inadequate tissue penetration) |
| Fosfomycin tromethamine | 3 g PO single dose | Single dose | No adjustment needed for CrCl >30 mL/min; use caution if <30 mL/min | Single-dose convenience improves adherence; broad-spectrum activity including multidrug-resistant E. coli |
| Ciprofloxacin | 250-500 mg PO twice daily | 3 days (uncomplicated); 7-14 days (complicated/pyelonephritis) | CrCl 30-50: 250-500 mg q12h; CrCl <30: 250-500 mg q18h | Reserve for complicated UTI or pyelonephritis; excellent tissue penetration |
For complicated UTI or pyelonephritis: Consider ceftriaxone 1-2 g IV/IM daily, cefepime 1-2 g IV q12h, or piperacillin-tazobactam 3.375 g IV q6h pending clinical severity. Ertapenem 1 g IV daily provides coverage if extended-spectrum beta-lactamase (ESBL) suspected. Trimethoprim-sulfamethoxazole 160/800 mg PO twice daily for 3 days remains an option if local E. coli resistance <20%, though empiric use declining due to rising resistance rates.
82-year-old female with UTI caused by Escherichia coli harboring tetB resistance gene (tetracycline resistance). Treatment options include nitrofurantoin, fosfomycin, or fluoroquinolones for uncomplicated cystitis; complicated infections may require IV beta-lactams. Avoid tetracyclines. Age-related considerations include renal function assessment, polypharmacy review, and increased risk for adverse drug events.
E. coli accounts for 75-95% of uncomplicated UTIs and remains the most common uropathogen in elderly women. The tetB gene encodes an efflux pump conferring resistance to tetracyclines but does not affect other antibiotic classes, preserving multiple treatment options.
The following regimen(s) are based on generally accepted and peer-reviewed antimicrobial activity of specific agents against detected pathogens, resistance genes, and presumed diagnosis based on specimen source and resulting pathogens. Antimicrobial activity and efficacy of agents for treatment of detected pathogens is not guaranteed. Medication selection, dosages, durations, and considerations are in congruence with clinical practice guidelines (IDSA, CDC, AAP, etc), when guidance is available. Additional patient factors including but not limited to HPI, comorbidities, concomitant medications, etc. should be carefully evaluated in conjunction with listed treatment considerations. Clinical correlation and appropriate medical judgment is warranted prior to prescribing a course of treatment.
Disclaimer: Although pathogen(s) were detected by PCR, these results should be interpreted in combination with clinical symptoms and are intended to inform, not replace, clinical judgment. Quantitative ranges of Low, Medium, and High are semi-quantitative estimates based on amplification curves. CFU values are approximations derived from PCR correlations established within the clinical laboratory. Resistance gene detection identifies common published genetic markers; however, absence of detected genes does not exclude phenotypic resistance through alternative mechanisms. The prescribing physician maintains full responsibility for treatment decisions, considering patient-specific factors, local resistance patterns, and clinical response. This report does not establish a physician-patient relationship between the consulting pathologist and the patient.
Detected organisms and resistance markers are surfaced at the top with clinical context, not buried in a results dump. The provider sees what was found and why it matters.
Dose, duration, renal adjustment, and clinical considerations laid out for each option. The narrowest effective therapy comes first. Alternatives are explicit. Therapies to avoid are flagged.
Age, renal function, drug interaction risks, and complicated-versus-uncomplicated assessment all incorporated. The recommendation is not generic. It is for this patient.
Follow-up timepoints, immediate and long-term prevention strategies, and clinical pearls give the provider an actionable plan that extends beyond the prescription itself.